FDA grants priority review for Novartis' Gleevec

08/27/2008 | Reuters

Gleevec, Novartis' cancer drug, obtained priority-review status from the FDA as primary post-surgery treatment for gastrointestinal stromal tumors. The company is seeking approval based on clinical results showing that Gleevec lowered the risk of GIST after surgery by 89%.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park